SAN DIEGO, July 8, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against CannTrust Holdings Inc. ("CannTrust") (NYSE: CTST) for violations of federal securities laws. CannTrust produces and distributes medical and recreational cannabis in Canada.On

CHICAGO, July 8, 2019 /PRNewswire/ -- Kalderos Director of Industry Relations Steve Zielinski will address the significance of duplicate discounts and how Kalderos' da

TARRYTOWN, N.Y., July 8, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2019 financial and operating results on Tuesday, August 6, 2019, before the U.S. financial markets open.  The Company will host a conference call and simultaneous webca

IRVINE, Calif., July 8, 2019 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today new clinical data from its ongoing glioblastoma Phase 2 clinical trial, investigating AIVITA's platform immunotherapy targeting cancer stem cells. Blood plasma biomarker analyses have identified predictive markers of e

HOD HASHARON, Israel, July 8, 2019 /PRNewswire/ -- Wize Pharma, Inc. (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced today that it has retained Lighthouse BioPartners, LLC a US-based firm specialized in partnering and financial adv

WATERTOWN, Mass., July 8, 2019 /PRNewswire/ -- EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, commercially launched DEXYCU® (dexamethasone intraocular suspension) 9% in March 2019 in the United States

--- Shipments to commence immediately from the Company's Mississauga, Ontario facility TORONTO, July 8, 2019 /PRNewswire/ - TerrAscend Corp. (CSE: TER; OTCQX: TRSSF) ("TerrAscend" or the "Company") today announced that its subsidiary, TerrAscend Canada, has received an amendment to its license from H

PLYMOUTH MEETING, Pa., July 8, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has completed enrollment in its Phase 2 trial with VGX-3100 in patients with precancerous lesions of the vulva or vulvar intraepithelial neoplasia (VIN). VGX-3100 is an immunotherapy that targets human papillomavirus (HPV) 16 and 18 and is being stud

MOUNTAIN VIEW, Calif., July 8, 2019 /PRNewswire/ -- IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of engineered

BRYAN, Texas, July 8, 2019 /PRNewswire/ -- As one of the leading drug and alcohol treatment centers in the state of Texas, More Than Rehab can now accept Magellan and Blue Cross Blue Shield in-network PPO and HMO insurance plans. This will help to reduce the out-of-pocket costs for those who have been struggling with addiction and ot